protein intake optimization glp-1 receptor agonists Investigating nutrient during use of glucagon-like peptide-1 agonist: a cross-sectional study Neurobiological Mechanisms and Therapeutic Potential

[DOI] [PMC free article] [PubMed] [Google Scholar] 105.J.R

This comes from both increased calorie burning (higher resting metabolic rate) and enhanced fat mobilization from storage

Found is not affiliated or endorsed by Novo Nordisk A/S., the owner of the registered trademarks Wegovy, Ozempic, Saxenda, and Victoza, nor is it affiliated or endorsed by Eli Lilly & Co., the owner of the registered trademarks Zepbound, Mounjaro, and Foundayo

JACC 84(17):16151628 Wallner M, Biber ME, Stolfo D, Sinagra G, Benson L, Dahlstrm U et al (2024) Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries

The company is also pursuing other approaches, including a drug called CagriSema that combines semaglutide the active ingredient in Ozempic and Wegovy with cagrilintide, which targets another hormone called amylin

The Great (Oral) GLP-1 Scare Why the Stevanato narrative is flawed This is not something that should take you by surprise because Ive talked about it in the past, but Stevanatos stock has been weak lately (maybe an understatement): This has happened despite the company (imho) receiving incrementally positive news over the past few months